Kezar Life Sciences, Inc.
KZR
$4.50
$0.102.27%
NASDAQ
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -29.20% | -31.58% | -22.39% | -6.26% | 52.38% |
| Gross Profit | 29.20% | 2.96% | 22.39% | 6.26% | -52.38% |
| SG&A Expenses | -3.73% | -35.08% | -3.15% | 5.37% | 11.30% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -24.04% | -32.52% | -18.23% | -3.32% | 41.77% |
| Operating Income | 24.04% | 14.02% | 18.23% | 3.32% | -41.77% |
| Income Before Tax | 37.33% | 12.08% | 11.36% | 2.44% | -77.44% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | 37.33% | 12.08% | 11.36% | 2.44% | -77.44% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 37.33% | 12.08% | 11.36% | 2.44% | -77.44% |
| EBIT | 24.04% | 14.02% | 18.23% | 3.32% | -41.77% |
| EBITDA | 24.20% | 14.10% | 18.45% | 3.35% | -42.19% |
| EPS Basic | -24.89% | 12.42% | 11.83% | 3.07% | -76.21% |
| Normalized Basic EPS | -54.62% | 12.42% | 17.89% | 3.07% | -42.42% |
| EPS Diluted | -24.89% | 12.42% | 11.83% | 3.07% | -76.21% |
| Normalized Diluted EPS | -54.62% | 12.42% | 17.89% | 3.07% | -42.42% |
| Average Basic Shares Outstanding | 0.36% | 0.39% | 0.53% | 0.65% | 0.70% |
| Average Diluted Shares Outstanding | 0.36% | 0.39% | 0.53% | 0.65% | 0.70% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |